___

• 1-Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16: 397-415.2- Padwal RS, Majumdar SR. Drug treatments for obesity:orlistat,sibutramine and rimonabant. Lancet.2007; 369: 71-7. 3-Sjostrom L, Narbo K, Sjostrom CD etal. Effects of bariatric surgery on mortality on swedish obese subjects. N Eng J Med. 2007; 357: 741-52. 4-Bourinbair AS, Jirathitikal V. Effect of oral immunisation with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices. Vaccine. 2010; 28:2763-8. 5- Haffer KN. Effects of novel vaccines on weight loss in diet induced obese mice. J Anim Sci Biotechnol. 2012; 3:21-4. 6- Hansotin T, Maida A, Flock G et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight and energy expenditure.J Clin Invest. 2007;117:143-52. 7- Wortley KE, del Rincon JP, Murray JD et al. Absence of ghrelin protects against early-onset obesity. J Clin Invest. 2005; 115:3573-8. 8- Lu SC, Xu J, Chinookoswong N et al. An acyl-ghrelin-specific neutralizing antibody inhibits the acute ghrelin-mediated orexigenic effects in mice. Mol Pharmacol. 2009; 75:901- 7. 9- Zakhari JS, Zorrilla EP, Zhou B, Mayorov AV, Janda KD. Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice. Mol Pharm. 2012; 9:281-9. 10- Jerry R Colca. Discontinued drugs in 2006: renal, endocrine and metabolic drugs. Expert Opin Inv Drug. 2007;16:1517-23.11- Moran TH, Dailey MJ. Gut peptides: targets for anti-obesity drug development? Endocrinology. 2009;150:2526-30. 12- Vizcarra JA, Kirby JD, Kim SK, Galyean ML. Active immunization against ghrelin decreases weight gain and alters plasma concentrations of growth hormone in growing pigs. Domest Anim Endocrinol. 2007; 33:176-89. 13- . Zorrilla EP, Iwasaki S, Moss JA et al. Vaccination against weight gain. Proc Natl Acad Sci. 2006; 103:13226-31.14- Kellokoski E, Kummu O, Serpi R et al. Ghrelin vaccination decreases plasma MCP-1 level in LDLR(-/-)- mice. Peptides 2009; 30:2292-300.15- Jennings GT, Bachmann MF. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol. 2009; 49:303-26.16- Brown MJ. Therapeutic potential of vaccines in the management of hypertension. Drugs. 2008;68:2557-60.17- Bachmann MF, Jennings GT. Therapeutic vaccines for chronic diseases: successes and technical challanges. Philos Trans R Soc Lond Biol Sci. 2011;366:2815-22.18- Andrade S, Pinho F, Ribeiro AM et al. Immunization against active ghrelin using virus-like particles for obesity treatment. Curr Pharm Des. 2013; 19:6551-8.19- Phase I/IIa Clinical Trial with Obese Individuals Shows no Effect of CYT009-GhrQb on Weight Loss. [(accessed on 3 January 2015)]; Available online: http://www.evaluategroup.com/Universal/View.aspx.20- Campitelli MA, Rosella LC, Kwong JC. The association between obesity and outpatient visits for acute respiratory infections in ontario, Canada. Int J Obes. 2014; 38: 113–9. 21- Mullen JT, Moorman DW, Davenport DL. The obesity paradox: Body mass index and outcomes in patients undergoing nonbariatric general surgery. Ann Surg. 2009; 250: 166-72.22- Arslan E, Atilgan H, Yavasoglu I. The prevalence of helicobacter pylori in obese subjects. Eur J Intern Med. 2009; 20: 695-7. 23- Uberos J, Molina-Carballo A, Fernandez-Puentes V, Rodriguez-Belmonte R, Munoz-Hoyos A. Overweight and obesity as risk factors for the asymptomatic carrier state of neisseria meningitidis among a paediatric population. Eur J Clin Microbiol Infect Dis. 2010; 29: 333-4.24- Morgan OW, Bramley A, Fowlkes A et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza a(h1n1) disease. PLoS ONE 2010; 5: e9694. 25- Dhurandhar NV. Insulin sparing action of adenovirus 36 and its e4orf1 protein. J Diabetes Complicat. 2013; 27: 191-9. 26-Ponterio E, Gnessi L. Adenovirus 36 and Obesity: An Overview. Viruses. 2015; 7:3719-40.27- Ergin S, Altan E, Pilanci O et al. The role of adenovirus 36 as a risk factor in obesity: The first clinical study made in the fatty tissues of adults in Turkey. Microb Pathog. 2015; 80: 57-62. 28- Karamese M, Altoparlak U, Turgut A, Aydogdu S, Karamese SA. The relationship between adenovirus-36 seropositivity, obesity and metabolic profile in Turkish children and adults. Epidemiol Infect. 2015; 16:1-7. 29- Wang ZQ, Cefalu WT, Zhang XH et al. Human adenovirus type 36 enhances glucose uptake in diabetic and nondiabetic human skeletal muscle cells independent of insulin signaling. Diabetes. 2008; 57:1805-13. 30- Na HN, Nam JH. Adenovirus 36 as an obesity agent maintains the obesity state by increasing mcp-1 and inducing inflammation. J Infect Dis 2012; 205:914-22. 31- Pasarica M, Loiler S, Dhurandhar NV. Acute effect of infection by adipogenic human adenovirus ad36. Arch Virol 2008: 153: 2097-102. 32- Na HN, Nam JH. Proof-of-concept for a virus-induced obesity vaccine; vaccination against the obesity agent adenovirus 36. Int J Obes. 2014; 38: 1470-4. 33- Börgeson E, Johnson AM, Lee YS et al. Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease. Cell Metabolism. 2015;22:125-37. 34- Rodriguez A, Durán A, Selloum M et al. Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metabolism. 2006;3:211-22. 35- Halenova T, Savchuk O, Ostapchenko L et al. P62 plasmid can alleviate diet-induced obesity and metabolic dysfunctions. Oncotarget. 2017; 8: 56030-40.36- Hotamisligil GS, Johnson RS, Distel RJ et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science. 1996; 274: 1377-9.